Role for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma
Mené sur 310 patients atteints d'un carcinome urothélial de stade localement avancé inopérable ou métastatique, cet essai international de phase II évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité de l'atézolizumab après l'échec d'une chimiothérapie à base de sels de platine
Programmed death ligand 1 (PD-L1) expressed on the tumour cell surface, or on neighbouring host immune cells in the tumour microenvironment, engages the programmed death 1 (PD-1) receptor on activated cytotoxic T cells and thus downregulates the tumour-directed host immune response. Dismantling of this negative feedback loop is at the core of novel cancer immunotherapeutic strategies. Anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors have shown good efficacy against several types of solid tumours in patients with advanced melanoma, non-small-cell lung cancer, renal cell carcinoma, and some types of colon cancer.
The Lancet , commentaire, 2015